Wall Street Zen upgraded shares of Clene (NASDAQ:CLNN – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday,Wall Street Zen reports.
Several other research analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating on shares of Clene in a research report on Monday, October 19th. Weiss Ratings cut Clene from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 27th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $34.00.
Check Out Our Latest Stock Report on Clene
Clene Stock Performance
Shares of NASDAQ CLNN opened at $4.38 on Friday. The firm has a 50 day moving average price of $3.90 and a two-hundred day moving average price of $5.13. The stock has a market cap of $56.90 million, a P/E ratio of -1.68 and a beta of 1.04. Clene has a 52-week low of $3.02 and a 52-week high of $10.84.
Clene (NASDAQ:CLNN – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.50. The business had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.07 million. Analysts predict that Clene will post -1.05 earnings per share for the current fiscal year.
Clene Company Profile
Clene Inc is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. The company’s lead product candidate, CNM-Au8, is an investigational oral suspension containing catalytically active gold nanocrystals designed to support cellular energy production and reduce oxidative stress, with the goal of protecting and improving the function of nerve cells.
Clene has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), and has also investigated its potential applications in other neurodegenerative disorders.
Featured Articles
- Five stocks we like better than Clene
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.
